TP53, a promising tumor treatment target (Mirgayazova et al., 2019) and ACACA were the two FRGs with the highest mutation rates (55% each), while the mutation rates of the remaining FRGs were all below 5%. This evidence concerns the gene TP53 and neoplasm.